FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 189 filers reported holding FATE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 4.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $117 | +192.5% | 31,185 | +63.9% | 0.00% | – |
| Q3 2023 | $40 | -65.2% | 19,031 | -21.5% | 0.00% | -100.0% |
| Q2 2023 | $115 | -79.2% | 24,251 | -75.1% | 0.00% | -80.0% |
| Q1 2023 | $554 | -77.7% | 97,235 | -60.4% | 0.01% | -86.1% |
| Q4 2022 | $2,480 | -99.6% | 245,758 | +864.7% | 0.04% | +414.3% |
| Q3 2022 | $571,000 | -29.6% | 25,474 | +86.1% | 0.01% | -36.4% |
| Q3 2021 | $811,000 | -6.8% | 13,686 | +36.6% | 0.01% | +10.0% |
| Q2 2021 | $870,000 | -29.9% | 10,020 | -26.6% | 0.01% | -16.7% |
| Q4 2020 | $1,241,000 | +364.8% | 13,651 | +13.6% | 0.01% | -20.0% |
| Q1 2020 | $267,000 | – | 12,014 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |